Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles

被引:2
|
作者
Hoo, Grace Si Ru [1 ]
Liew, Yi Xin [2 ]
Kwa, Andrea Lay-Hoon [2 ,3 ,4 ]
机构
[1] Tan Tock Seng Hosp, Dept Pharm, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Pharm, Outram Rd, Singapore 169608, Singapore
[3] Duke Natl Univ Singapore, Emerging Infect Dis, Singapore, Singapore
[4] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore, Singapore
关键词
Antimicrobial dosing; optimisation; pharmacokinetic; pharmacodynamic; CRITICALLY-ILL PATIENTS; RESISTANT STAPHYLOCOCCUS-AUREUS; RENAL REPLACEMENT THERAPY; BETA-LACTAM ANTIBIOTICS; TERM INTRAVENOUS-INFUSION; ACUTE KIDNEY INJURY; INTERMITTENT INFUSION; PSEUDOMONAS-AERUGINOSA; CLINICAL-IMPLICATIONS; INTENSIVE-CARE;
D O I
10.4103/ijmm.IJMM_17_278
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
While suboptimal dosing of antimicrobials has been attributed to poorer clinical outcomes, clinical cure and mortality advantages have been demonstrated when target pharmacokinetic (PK) and pharmacodynamic (PD) indices for various classes of antimicrobials were achieved to maximise antibiotic activity. Dosing optimisation requires a good knowledge of PK/PD principles. This review serves to provide a foundation in PK/PD principles for the commonly prescribed antibiotics (beta-lactams, vancomycin, fluoroquinolones and aminoglycosides), as well as dosing considerations in special populations (critically ill and obese patients). PK principles determine whether an appropriate dose of antimicrobial reaches the intended pathogen(s). It involves the fundamental processes of absorption, distribution, metabolism and elimination, and is affected by the antimicrobial's physicochemical properties. Antimicrobial pharmacodynamics define the relationship between the drug concentration and its observed effect on the pathogen. The major indicator of the effect of the antibiotics is the minimum inhibitory concentration. The quantitative relationship between a PK and microbiological parameter is known as a PK/PD index, which describes the relationship between dose administered and the rate and extent of bacterial killing. Improvements in clinical outcomes have been observed when antimicrobial agents are dosed optimally to achieve their respective PK/PD targets. With the rising rates of antimicrobial resistance and a limited drug development pipeline, PK/PD concepts can foster more rational and individualised dosing regimens, improving outcomes while simultaneously limiting the toxicity of antimicrobials.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 50 条
  • [31] Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis
    Wang, Ya-Kun
    Wu, Yue-E
    Li, Xue
    Tian, Li-Yuan
    Khan, Muhammad Wasim
    Tang, Bo-Hao
    Shi, Hai-Yan
    Zheng, Yi
    Hao, Guo-Xiang
    van den Anker, John
    You, Dian-Ping
    Zhao, Wei
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [32] Vancomycin dose optimisation comparing a pharmacokinetic/pharmacodynamic model versus the pharmacokinetic model
    Linana Granell, Carla
    Belles Medall, M. Dolores
    Ferrando Piqueres, Raul
    Montanes Pauls, Belen
    Alvarez Martin, Tamara
    Mendoza Aguilera, Maria
    Garcia Martinez, Teresa
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2019, 26 (01) : 16 - 22
  • [33] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [34] Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
    Elisabeth C Jeunesse
    Marc Schneider
    Frederique Woehrle
    Mathieu Faucher
    Herve P Lefebvre
    Pierre-Louis Toutain
    BMC Veterinary Research, 9
  • [35] Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
    Jeunesse, Elisabeth C.
    Schneider, Marc
    Woehrle, Frederique
    Faucher, Mathieu
    Lefebvre, Herve P.
    Toutain, Pierre-Louis
    BMC VETERINARY RESEARCH, 2013, 9
  • [36] Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance
    Simpson, JA
    Watkins, ER
    Price, RN
    Aarons, L
    Kyle, DE
    White, NJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) : 3414 - 3424
  • [37] Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited
    Cunha, Burke A.
    Baron, Jeffrey
    Cunha, Cheston B.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2017, 15 (03) : 257 - 267
  • [38] Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects
    Czock, David
    Keller, Frieder
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (06) : 727 - 751
  • [39] Pharmacodynamic and pharmacokinetic optimisation of treatment with β-lactam antibiotics in cystic fibrosis
    Vinks, AATMM
    Mouton, JW
    Heijerman, HGM
    Bakker, W
    REVIEWS IN MEDICAL MICROBIOLOGY, 1999, 10 (02) : 89 - 107
  • [40] Dose optimisation in clinical oncology: Pharmacokinetic-pharmacodynamic relationships
    Canal, P
    Chatelut, E
    BULLETIN DU CANCER, 1996, 83 (04) : 256 - 265